[Aromatase inhibitors: pharmacological aspects]

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Aromatase inhibitors are crucial for treating hormone-dependent breast cancer in postmenopausal women.
• Aromatase enzymes convert androgens to estrogens, with peripheral aromatization being the primary source of estrogens in postmenopausal women.
• Selective inhibition of estrogen production via aromatase inhibitors is an effective therapeutic strategy.

Purpose of the Study:

• To review the role and advancements in selective aromatase inhibitors for breast cancer treatment.
• To differentiate between steroidal (Type I) and non-steroidal (Type II) aromatase inhibitors.
• To highlight the increased potency and specificity of second and third-generation aromatase inhibitors.

Main Methods:

• Review of scientific literature on aromatase inhibitors.
• Classification of aromatase inhibitors into Type I (irreversible, steroidal) and Type II (reversible, non-steroidal).
• Comparison of the efficacy and specificity of different generations of aromatase inhibitors.

Main Results:

• Selective aromatase inhibition is a key strategy in treating estrogen-dependent breast cancer.
• Aromatase inhibitors are categorized into steroidal (Type I) and non-steroidal (Type II) compounds.
• Second and third-generation aromatase inhibitors demonstrate significantly higher potency and specificity compared to first-generation agents like aminoglutethimide.

Conclusions:

• Selective aromatase inhibitors represent a significant advancement in breast cancer therapy.
• The development of more potent and specific inhibitors (second and third generation) has improved treatment outcomes.
• Aromatase inhibitors provide a targeted approach to reducing estrogen levels in postmenopausal women with breast cancer.